Yorvipath 168MCG INJ, soln, pen
Ended Awarded Last action
- Contract number
- 36C26025F0329
- Awardee
-
Ascendis Pharma, Inc. UEI UKN2MTNJ9WM5
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $210,118
Award facts
- Contract value 100% obligated
- $210,117.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15205, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $30 | |
| Original award | $210,088 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 20, awarded a delivery order valued at $210,117.92 to Ascendis Pharma, Inc. for the supply of Yorvipath 168 mcg injection solution pen, including a fiscal year 2026 price increase. This firm fixed-price contract, awarded on July 15, 2025, with an ultimate completion date of July 14, 2026, represents a direct award with no set-aside designation. The pharmaceutical will be delivered to a VA facility in Pittsburgh, Pennsylvania. Ascendis Pharma is a foreign-owned pharmaceutical company specializing in rare disease treatments and has established itself as a key supplier of specialized medications to the VA healthcare system.
This delivery order is issued under Ascendis Pharma's $59.8 million multiple-award Federal Supply Schedule contract on the Pharmaceuticals and Drugs (FSS-61-IB) schedule, valid through July 14, 2027, as well as the company's $7.3 million single-award Blanket Purchase Agreement with the VA National Acquisition Center. These indefinite delivery vehicles enable the VA to procure critical pharmaceutical products through streamlined task order mechanisms to support specialized medical treatment needs for veterans. Yorvipath is a treatment for growth hormone deficiency, reflecting the company's focus on addressing complex medical conditions within the veteran population.
Quick answers
Who was awarded contract 36C26025F0329?
36C26025F0329 was awarded to Ascendis Pharma, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on July 15, 2025.
How much is contract 36C26025F0329 worth?
The government has obligated $210,118 on 36C26025F0329.
Is contract 36C26025F0329 an order under another contract?
Yes. 36C26025F0329 is a delivery order under 36F79722D0166, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0329 competed?
The extent of competition for 36C26025F0329 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award